12:00 Diagnosis and Treatment of Barrett’s Esophagus December 2, 2022 • Gastroenterology James East, MD, of @MayoClinicUK discusses #BarrettsEsophagus.
3:04 Combination Therapy Options for Blast Phase CML Treatment November 25, 2022 • CML Content Hub @CoplandMhairi, of @UofGlasgow, discusses #combination #therapy for #CML.
56:45 Emerging and Re-emerging Pediatric Infectious Diseases in 2022 November 25, 2022 • Infectious Diseases @cecejohnson_md, Lisa Saiman, MD, Jason Zucker, MD, and Natalie Neu, MD, discuss #emerging #pediatric #infectiousdiseases.
1:11 Reducing Dosage to Manage Side Effects of Long-Term TKI Use November 20, 2022 • CML Content Hub @CoplandMhairi, of @UofGlasgow, discusses #management of #side effects with long-term #TKI use.
6:40 Successful Treatment-Free Remission in Patients With CML After TKI Discontinuation November 18, 2022 • CML Content Hub @FadiHaddad_MD, of @MDAndersonNews, discusses treatment-free remission in #CML.
26:24 Novel Strategies for Treating Meningiomas November 8, 2022 • Neurology Nancy Ann Oberheim Bush, MD, PhD, of @NeurosurgUCSF, discusses #emerging #therapy for #meningiomas.
Physician Burnout: Addressing the Rapid Increase November 8, 2022 • Business of Medicine Christine Sinsky, MD, and Todd Unger, of @AmerMedicalAssn, discuss physician #burnout.
7:06 Timing Discontinuation of Treatment: Critical to Maximize Chances of Successful TFR November 5, 2022 • CML Content Hub @FadiHaddad_MD, of @MDAndersonNews, discusses #treatment #discontinuation in #CML.
:39 Additional Chromosomal Abnormalities in CML: An Indication for Close Monitoring November 3, 2022 • CML Content Hub Susanne Saussele, MD, discusses the importance of #chromosome #abnormalities in #CML.
:59 FLOT2 Deficiency and Prolonged Survival in CML November 2, 2022 • CML Content Hub Daniela Krause, MD, of @goetheuni, discusses #FLOT2 deficiency and #survival in #CML.
1:09 Selecting CML Patients Eligible for Treatment Cessation November 2, 2022 • CML Content Hub Susanne Saussele, MD, discusses #treatment #discontinuation in #CML.
1:02 Votobatinib Promising in Phase 1/2 Trial of Mostly Heavily Pretreated CML Patients November 1, 2022 • CML Content Hub @GCC_Cortes, of @GACancerCenter, discusses #votobatinib in #CML.
